TY - JOUR
KW - Buprenorphine, Naloxone Drug Combination
KW - Humans
KW - naloxone
KW - Nasal Sprays
KW - Opioid-Related Disorders/drug therapy
KW - Pharmacies
KW - Texas
KW - buprenorphine
KW - Harm Reduction
KW - Opioid-use disorder
KW - treatment
KW - youths
AU - M. S. Toce
AU - S. E. Hadland
A1 - 
AB - Numerous barriers exist for patients attempting to access treatment for opioid-use disorder and/or naloxone, with geographical, racial, and age-related differences exacerbating these hardships.
AD - Division of Emergency Medicine, Boston Children's Hospital, Boston, MA, USA.; Department of Pediatrics, Harvard Medical School, Boston, MA, USA.; Harvard Medical Toxicology Program, Boston, MA, USA.; Department of Pediatrics, Boston Medical Center, Boston, MA, USA.; Division of General Pediatrics, Boston University School of Medicine, Boston, MA, USA.
BT - Addiction (Abingdon, England)
C5 - Healthcare Disparities; Opioids & Substance Use
CP - 6
DO - 10.1111/add.15375
IS - 6
JF - Addiction (Abingdon, England)
LA - eng
M1 - Journal Article
N2 - Numerous barriers exist for patients attempting to access treatment for opioid-use disorder and/or naloxone, with geographical, racial, and age-related differences exacerbating these hardships.
PY - 2021
SN - 1360-0443; 0965-2140; 0965-2140
SP - 1512
EP - 1513
EP - 
T1 - Commentary on Hill et al.: Breaking down barriers-increasing access to lifesaving opioid use disorder medications to save lives
T2 - Addiction (Abingdon, England)
TI - Commentary on Hill et al.: Breaking down barriers-increasing access to lifesaving opioid use disorder medications to save lives
U1 - Healthcare Disparities; Opioids & Substance Use
U2 - 33403685
U3 - 10.1111/add.15375
VL - 116
VO - 1360-0443; 0965-2140; 0965-2140
Y1 - 2021
Y2 - Jun
ER -